Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | REV1 | Q9UBZ9 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.32 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.32 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16886320 | 0.80 | LMNA (0.40) | GAAMAPTLMNAPOLBSMN1; SMN2 | |
| SCHEMBL13629873 | 0.80 | POLB (0.60) | LMNAPOLBSMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL16892267 | 0.79 | MAPT (0.42) | GAAMAPTLMNASMN1; SMN2MEN1 | |
| SCHEMBL20827094 | 0.79 | EPHX2 (0.50) | MAPTPOLBSMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL22962051 | 0.78 | GNAI3 (0.41) | GAAMAPTLMNAPOLBALDH1A1 | |
| SCHEMBL13804074 | 0.76 | GAA (0.42) | GAAMAPTLMNAPOLBSMN1; SMN2 | |
| SCHEMBL13116120 | 0.74 | SMN1; SMN2 (0.44) | GAALMNAPOLBSMN1; SMN2ALDH1A1 | |
| SCHEMBL190928 | 0.74 | CYP1A2 (0.48) | SMN1; SMN2EPHX2EPHX1 | |
| SCHEMBL20880179 | 0.73 | GAA (0.37) | GAAMAPTLMNAPOLBSMN1; SMN2 | |
| SCHEMBL1137939 | 0.73 | LMNA (0.41) | GAAMAPTLMNASMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3092229-B1 | PYRROLIDINYL SULFONE DERIVATIVES AND THEIR USE AS ROR GAMMA MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2018-03-28 | — | — | EP | disclosed |
| US-20160326108-A1 | PYRROLIDINYL SULFONE DERIVATIVES AND THEIR USE AS ROR GAMMA MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2016-11-10 | — | — | US | disclosed |
| US-9458171-B2 | Pyrrolidinyl sulfone RORγ modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-10-04 | — | — | US | disclosed |
| US-20150191483-A1 | PYRROLIDINYL SULFONE RORGAMMA MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2015-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160326108-A1 | PYRROLIDINYL SULFONE DERIVATIVES AND THEIR USE AS ROR GAMMA MODULATORS | RORC, RORB, RORA | GAA 1742/4885MAPT 385/4885LMNA 4085/4885 |
| US-20150191483-A1 | PYRROLIDINYL SULFONE RORGAMMA MODULATORS | RORC, RORB, RORA | GAA 1512/4885MAPT 314/4885LMNA 3963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.